



## ESC Declaration of Interest Report

### 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the *ESC Declaration and Management of Conflict of Interest Policy*. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved by the ESC in July 2020.

The most up-to-date version of the policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Badagliacca Roberto	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : pulmonary hypertension</li> <li>- United Therapeutics : pulmonary hypertension</li> <li>- Bayer Healthcare : pulmonary hypertension</li> <li>- Ferrer Internacional : pulmonary hypertension</li> <li>- Galenica Vifor : pulmonary hypertension</li> <li>- MSD : pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension</li> <li>- GSK : pulmonary hypertension</li> <li>- Dompè : pulmonary hypertension</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : pulmonary hypertension</li> <li>- United Therapeutics : pulmonary hypertension</li> <li>- Bayer Healthcare : pulmonary hypertension</li> <li>- Ferrer Internacional : pulmonary hypertension</li> <li>- Galenica Vifor : pulmonary hypertension</li> <li>- MSD : pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension</li> <li>- GSK : pulmonary hypertension</li> <li>- Dompè : pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Berger Rolf	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pediatric Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pediatric Pulmonary Hypertension</li> <li>- Lilly : Pediatric Pulmonary Hypertension</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Stichting Hartekind, committee of recommendation (patient organisation advocacy)</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pediatric Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pediatric Pulmonary Hypertension</li> <li>- Lilly : Pediatric Pulmonary Hypertension</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- - Stichting Hartekind, committee of recommendation (patient organisation advocacy) - Association for Pediatric Pulmonary Hypertension, Executive board member TOPP-registry (Tracking Outcome and Practice in Pediatric Pulmonary Hypertension)</li> </ul>
Brida Margarita	<p><b>2020</b></p> <p>Nothing to be declared</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Brida Margarita	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Krka Pharma : Adult congenital heart disease education webinar</p>
Carlsen Joern	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : Pulmonary hypertension and right heart failure (speaker fee) - Ferrer Internacional : Pulmonary hypertension and right heart failure (speaker fee) - Janssen-Cilag : Pulmonary hypertension and right heart failure (speaker fees, advisory board fees)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Janssen-Cilag : Pulmonary hypertension and right heart failure</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag AB, Solna, Sweden : Pulmonary hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : Pulmonary hypertension and right heart failure (speaker fees, advisory board fees)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Janssen-Cilag : Pulmonary hypertension and right heart failure</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Coats Andrew	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Faraday Australia : Acute MI</li> <li>- CVRx : Autonomic devices</li> <li>- ESN Cleer : Biomarkers</li> <li>- Actimed : Cancer</li> <li>- Bayer AG (event review committee member) : CV disease</li> <li>- CorVia : Device for HFpEF</li> <li>- Cardiac Dimensions : Devices for MR</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- Menarini : Heart Failure</li> <li>- Astra Zeneca : Hyperkalaemia</li> <li>- Vifor International : Iron deficiency</li> <li>- Arena : New drug development in acute heart failure</li> <li>- Nutricia : Nutrition</li> <li>- WL Gore : Prosthetic Valves</li> <li>- Respicardia : Sleep Apnoea</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Faraday Australia : Acute MI</li> <li>- CVRx : Autonomic devices</li> <li>- ESN Cleer : Biomarkers</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Coats Andrew	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Actimed : Cancer</li> <li>- CorVia : Device for HFpEF</li> <li>- Cardiac Dimensions : Devices for MR</li> <li>- Boehringer-Ingelheim : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- Menarini : Heart Failure</li> <li>- Impulse Dynamics : Heart Failure</li> <li>- Viatris : Heart failure</li> <li>- Astra Zeneca : Hyperkalaemia</li> <li>- Vifor International : Iron deficiency</li> <li>- Arena : New drug development in acute heart failure</li> <li>- Respicardia : Sleep Apnoea</li> </ul>
Delcroix Marion	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : pulmonary embolism</li> <li>- Pfizer : pulmonary embolism</li> <li>- Bayer : pulmonary hypertension</li> <li>- Janssen-Cilag : pulmonary hypertension</li> <li>- MSD : pulmonary hypertension</li> <li>- Acceleron : pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Delcroix Marion	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Janssen-Cilag : pulmonary hypertension</p>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - INARI : pulmonary embolism - Bayer : pulmonary hypertension - Janssen-Cilag : pulmonary hypertension - Ferrer Internacional : pulmonary hypertension - MSD : pulmonary hypertension - AOP Orphan Pharmaceuticals : pulmonary hypertension - Acceleron : pulmonary hypertension</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Janssen-Cilag : pulmonary hypertension</p>
Escribano Subias Maria Pilar	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : Pulmonary hypertension - Ferrer Internacional : Pulmonary hypertension - Merck Sharp &amp; Dohme : Pulmonary hypertension - Acceleron : Pulmonary hypertension</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Escribano Subias Maria Pilar	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Ferrer Internacional : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary hypertension</li> <li>- Acceleron : Pulmonary hypertension</li> </ul>
Ferrari Pisana Maria	<p><b>2020</b></p> <p style="text-align: center;">Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p style="text-align: center;">Nothing to be declared</p>
Ghofrani Hossein Ardeschir	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Gossamer Bio : Pulmonary hypertension</li> <li>- Actelion : Pulmonary vascular disease</li> <li>- Johnson &amp; Johnson : Pulmonary vascular disease</li> <li>- Merck Sharp &amp; Dohme : Pulmonary vascular disease</li> <li>- Bayer AG : Pulmonary vascular disease</li> <li>- Acceleron : Pulmonary vascular disease</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary vascular disease</li> <li>- Johnson &amp; Johnson : Pulmonary vascular disease</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Ghofrani Hossein Ardeschir	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Pulmonary vascular disease</li> <li>- Bayer AG : Pulmonary vascular disease</li> <li>- Acceleron : Pulmonary vascular disease</li> <li>- Gossamer Bio : Pulmonary vascular disease</li> </ul>
Giannakoulas George	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Menarini : Chronic coronary artery disease, Cardiovascular Disease</li> <li>- Unipharma : Chronic coronary artery disease, Cardiovascular Disease</li> <li>- Astra Zeneca : Diabetes mellitus</li> <li>- Novartis : Heart Failure</li> <li>- Roche Diagnostics : Heart Failure</li> <li>- Servier : Hyperlipidemia</li> <li>- Vianex : Hyperlipidemia</li> <li>- Mylan : Hyperlipidemia</li> <li>- MSD : Pulmonary Hypertension</li> <li>- Actelion-Janssen : Pulmonary Hypertension</li> <li>- Elpen Pharmaceuticals : Pulmonary Hypertension, Hyperlipidemia</li> <li>- Leo Pharma : Thromboembolic Disease</li> <li>- Boehringer-Ingelheim : Thromboembolic Disease, Heart Failure</li> <li>- Pfizer : Thromboembolism</li> <li>- Bayer Healthcare : Thromboembolism, Chronic coronary artery disease</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Giannakoulas George	<p><b>2020</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- MSD : Pulmonary Hypertension</li> <li>- Actelion - Janssen : Pulmonary Hypertension</li> <li>- Leo Pharma : Thromboembolism</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- Galenica Greece : Pulmonary Hypertension</li> <li>- Pfizer : Atrial Fibrillation</li> <li>- Menarini : Coronary Artery Disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Roche Diagnostics : Heart Failure</li> <li>- Actelion Janssen : Pulmonary Hypertension</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular Disease</li> <li>- Astra Zeneca : Cardiovascular Disease</li> <li>- Boehringer-Ingelheim : Cardiovascular Disease</li> <li>- Pfizer : Cardiovascular Disease</li> <li>- Servier : Cardiovascular Disease</li> <li>- Sanofi Aventis : Cardiovascular Disease</li> <li>- Menarini : Cardiovascular Disease</li> <li>- Bayer Healthcare : Cardiovascular Disease</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Giannakoulas George	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : Cardiovascular Disease</li> <li>- Genesis Pharma : Cardiovascular Disease</li> <li>- Unipharma : Cardiovascular Disease</li> <li>- Novartis : Heart Failure</li> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- MSD : Pulmonary Hypertension</li> <li>- Bausch Health : Pulmonary Hypertension</li> <li>- Janssen Pharmaceutical : Pulmonary Hypertension</li> <li>- Ferrer Internacional/Galenica Greece : Pulmonary Hypertension</li> <li>- Elpen Pharmaceuticals : Pulmonary Hypertension, Cardiovascular Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Galenica Greece : Pulmonary Hypertension</li> <li>- Menarini : Coronary Artery Disease</li> <li>- Actelion Janssen : Pulmonary Hypertension</li> </ul>
Hoepfer Marius M	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- Bayer Healthcare : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> <li>- Acceleron : Pulmonary Hypertension</li> <li>- Actelion/Janssen : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Hoepfer Marius M	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Pfizer : Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- Bayer Healthcare : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> <li>- Acceleron : Pulmonary Hypertension</li> </ul>
Humbert Marc	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Ambrisentan, Epoprostenol</li> <li>- Johnson &amp; Johnson : Bosentan, Macitentan, Epoprostenol, Selexipag</li> <li>- Bayer : Riociguat</li> <li>- Merck Sharp &amp; Dohme : Riociguat</li> <li>- Acceleron : Sotatercept</li> <li>- Ferrer Internacional : Treprostinil</li> <li>- AOP Orphan Pharmaceuticals : Treprostinil</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Iloprost, Riociguat</li> <li>- Johnson &amp; Johnson : Pulmonary hypertension translational research</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Humbert Marc	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Asthma</li> <li>- Sanofi Aventis : Asthma</li> <li>- Astra Zeneca : Asthma, COPD</li> <li>- GlaxoSmithKline : Asthma, COPD</li> <li>- Chiesi Pharma : Pulmonary hypertension, asthma, COPD</li> <li>- Johnson &amp; Johnson : Pulmonary hypertension: Bosentan, Macitentan, Epoprostenol, Selexipag</li> <li>- Bayer : Pulmonary hypertension: Riociguat</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension: Riociguat</li> <li>- Altavant : Pulmonary hypertension: Rodatristat</li> <li>- Acceleron : Pulmonary hypertension: Sotatercept</li> <li>- Shou Ti : Pulmonary hypertension: translational research</li> <li>- Morphogenics : Pulmonary hypertension: translational research</li> <li>- Ferrer Internacional : Pulmonary hypertension: Treprostinil</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary hypertension: Treprostinil</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Pulmonary hypertension translational research</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension translational research</li> <li>- Acceleron : Pulmonary hypertension translational research</li> <li>- Shou Ti : Pulmonary hypertension translational research</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kiely David G	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Ferrer Internacional : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> <li>- Acceleron : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kiely David G	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Cardiology, Respiratory, Pulmonary Hypertension</li> <li>- Ferrer Internacional : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul>
Kovacs Gabor	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : COPD / ILD</li> <li>- Bayer : Pulmonary Hypertension</li> <li>- Ferrer Internacional : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : COPD, ILD</li> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Ferrer Internacional : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kovacs Gabor	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : ILD</li> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul>
Mayer Eckhard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Surgical and interventional treatment of CTEPH</li> <li>- Merck Sharp &amp; Dohme : Surgical and interventional treatment of CTEPH</li> <li>- Actelion/Janssen : Surgical and interventional treatment of CTEPH</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Actelion/Janssen : CTEPH adjudication committee</li> <li>- Bayer : Speakers fees</li> <li>- MSD : speakers fees</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Meszaros Gergely	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : consultancy</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- I am a consultant of the European Pulmonary Hypertension Association.</li> </ul>
	<p><b>2021</b></p> <p>Other Positions of Influence</p> <ul style="list-style-type: none"> <li>- I am a consultant of the European Pulmonary Hypertension Association.</li> </ul>
Nagavci Blin	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Olsson Karen	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Acceleron : Pulmonary hypertension</li> <li>- Acrtelion : Pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Olsson Karen	<p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Acceleron : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Actelion/ Janssen : Pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Acceleron : Pulmonary hypertension</li> <li>- Actelion/Janssen : Pulmonary hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Acceleron : Pulmonary hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Acceleron : Pulmonary hypertension</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Olsson Karen	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Acceleron : Pulmonary hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension</li> </ul>
Pepke-Zaba Joanna	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Quint Jennifer	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Asthma</li> <li>- Boehringer-Ingelheim : COPD</li> <li>- GlaxoSmithKline : COPD</li> <li>- Bayer AG : PAD</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Asthma and COPD</li> <li>- GlaxoSmithKline : COPD</li> <li>- Chiesi Pharma : COPD</li> <li>- Boehringer-Ingelheim : COPD, ILD</li> <li>- Bayer AG : PAD, CAD, HF</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Asthma</li> <li>- Boehringer-Ingelheim : COPD</li> <li>- GlaxoSmithKline : COPD</li> <li>- Bayer AG : PAD</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Asthma and COPD</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Quint Jennifer	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : COPD</li> <li>- Chiesi Pharma : COPD</li> <li>- Boehringer-Ingelheim : COPD, ILD</li> <li>- Bayer AG : PAD, CAD, HF</li> </ul>
Radegran Goran	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Advisory boards</li> <li>- Janssen-Cilag : Speaker fees, advisory boards</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion Pharmaceuticals : Investigator, PI</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Advisory boards</li> <li>- Janssen-Cilag : Speaker fees, advisory boards</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion Pharmaceuticals : Investigator, PI</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rosenkranz Stephan	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Vifor International : heart failure</li> <li>- MSD : heart failure, pulmonary hypertension</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Actelion : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Steering committee member</li> <li>- Bayer : Steering Committee member</li> <li>- Janssen-Cilag : Steering Committee member</li> <li>- Actelion : Steering Committee member</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Pulmonary Hypertension</li> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Actelion : Pulmonary Hypertension</li> <li>- Astra Zeneca : Pulmonary Hypertension / Heart Failure</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Vital : Cardiorenal syndrome</li> <li>- MSD : heart failure, pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rosenkranz Stephan	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Steering committee member</li> <li>- Bayer : Steering Committee member</li> <li>- Janssen-Cilag : Steering Committee member</li> <li>- Actelion : Steering Committee member</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Pulmonary Hypertension</li> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Astra Zeneca : Pulmonary Hypertension / Heart Failure</li> </ul>
Seraphim Ferreira Diogenes	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- I hold an honorary position as Adjunct Research Fellow at Monash University School of Public Health and Preventive Medicine, Melbourne, Australia.</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Other Positions of Influence</p> <ul style="list-style-type: none"> <li>- I have held until 26 April 2021 an honorary position as Adjunct Research Fellow at Monash University School of Public Health and Preventive Medicine, Melbourne, Australia.</li> </ul>
Simonneau Gerald	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Acceleron : Pulmonary Arterial Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Simonneau Gerald	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : pulmonary vascular disease</li> <li>- Bayer Healthcare : pulmonary vascular disease</li> <li>- Merck Sharp &amp; Dohme : pulmonary vascular disease</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Acceleron : Pulmonary Arterial Hypertension</li> <li>- Johnson &amp; Johnson : pulmonary vascular disease</li> <li>- Bayer Healthcare : pulmonary vascular disease</li> <li>- Merck Sharp &amp; Dohme : pulmonary vascular disease</li> </ul>
Sitbon Olivier	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Ferrer Internacional : Pulmonary Hypertension</li> <li>- MSD : Pulmonary Hypertension</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension</li> <li>- Gossamer Bio : Pulmonary Hypertension</li> <li>- Acceleron Pharmaceuticals : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pulmonary Hypertension</li> <li>- MSD : Pulmonary Hypertension</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitbon Olivier	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Ferrer Internacional : Pulmonary Hypertension</li> <li>- MSD : Pulmonary Hypertension</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension</li> <li>- Gossamer Bio : Pulmonary Hypertension</li> <li>- Acceleron Pharmaceuticals : Pulmonary Hypertension</li> </ul>
Tonia Thomy	<p><b>2020</b></p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Toshner Mark	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> <li>- Morphogen-IX : pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Toshner Mark	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> <li>- Morphogen-IX : pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension</li> </ul>
Vachier Jean-Luc	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Actelion : Pulmonary Hypertension</li> <li>- Bayer Healthcare : Pulmonary Hypertension</li> <li>- Bial Portela : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- PhaseBio : Pulmonary hypertension</li> <li>- Respira Therapeutics : Pulmonary hypertension</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart Failure</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Vachery Jean-Luc	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Novartis : Pulmonary Hypertension</li> <li>- Actelion : Pulmonary Hypertension</li> <li>- Bayer Healthcare : Pulmonary Hypertension</li> <li>- Bial Portela : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Acceleron : Pulmonary Hypertension</li> <li>- PhaseBio : Pulmonary hypertension</li> <li>- Respira Therapeutics : Pulmonary hypertension</li> <li>- Shouti : Pulmonary Hypertension</li> <li>- Altavant Science : Pulmonary Hypertension</li> </ul>
Vonk Noordegraaf Antonie	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : pulmonary hypertension</li> <li>- MSD : pulmonary hypertension</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : pulmonary hypertension</li> <li>- United Therapeutics : pulmonary hypertension</li> <li>- Bayer Schering Pharma : pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Vonk Noordegraaf Antonie	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : pulmonary hypertension</li> <li>- MSD : pulmonary hypertension</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : pulmonary hypertension</li> <li>- United Therapeutics : pulmonary hypertension</li> <li>- Bayer Schering Pharma : pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Abdullaev Timur	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology, Heart Failure</li> <li>- Polpharma : Cardiology, Heart Failure</li> </ul>
Aboyans Victor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Astrazeneca : Diabetes</li> <li>- Boehringer Ingelheim : Diabetes</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of the French Society of Cardiology</p>
Andreassen Arne Kristian	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Johnson &amp; Johnson : Pulmonary hypertension</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Johnson &amp; Johnson : Pulmonary hypertension</p>
Anton Ly	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : Consultaion Pulmonary Arterial Hypertension</p>
Arbustini Eloisa	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Charity - MAGICA ONLUS</p>
Asteggiano Riccardo	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself - Council of Cardio-Oncology ESC : cardio-oncology</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Bani Marjeh Mohammed Yassin	<p><b>2021</b></p> <p style="text-align: center;">Nothing to be declared</p>
Barbera Joan Albert	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Ferrer Internacional : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Acceleron Pharma : Pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> </ul>
Beghetti Maurice	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> <li>- GlaxoSmithKline : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : pulmonary hypertension</li> <li>- Bayer AG : pulmonary hypertension</li> <li>- Acceleron : pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Beghetti Maurice	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Gossamer : pulmonary hypertension</li> <li>- Altavant : pulmonary hypertension</li> <li>- orphacare : pulmonary hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> </ul>
Bulatovic Nebojsa	<p><b>2021</b></p> <p>Nothing to be declared</p>
Bush Andrew	<p><b>2021</b></p> <p>Nothing to be declared</p>
Celutkiene Jelena	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Chraibi Said	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - Actelion : Pulmonary hypertension</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself  - Actelion : Pulmonary Hypertension</p>
Cikes Maja	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - Pfizer : Amyloidosis  - GE Healthcare : Cardiovascular ultrasound  - Amicus Therapeutics : Fabry disease  - Astra Zeneca : Heart failure  - Bayer : Heart failure  - Boehringer-Ingelheim : Heart failure  - Teva Pharmaceutical Industries : Heart failure  - Krka Pharma : Heart failure  - Llvanova : Heart failure  - Novartis : Heart failure, hyperlipidaemia</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - CorVia : Heart failure</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Codreanu Andrei	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Mayo Clinic Cardiovascular Medicine Board Review Course</li> </ul>
Coghlan John G	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Pulmonary Hypertension</li> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Vicore : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : PHT</li> <li>- Merck Sharp &amp; Dohme : PHT</li> </ul>
Condliffe Robin	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul>
De Man Frances	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Arterial Hypertension</li> </ul>
Dinh-Xuan Tuan	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi-Genzyme : Asthma</li> <li>- Chiesi Pharma : Asthma &amp; COPD</li> <li>- Novartis : Asthma, COPD</li> <li>- GlaxoSmithKline : Asthma, COPD</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> <li>- Boston Scientific : Study</li> <li>- Biotronik : Study</li> <li>- Liva Nova : Study</li> </ul>
Fauchier Laurent	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Healthcare</li> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- Novo-Nordisk : Healthcare</li> <li>- Zoll Medical : Healthcare</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<b>2021</b> - XO : Healthcare
Gaine Sean	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Janssen-Cilag : PULMONARY HYPERTENSION</li> <li>- United Therapeutics : PULMONARY HYPERTENSION</li> <li>- Bayer AG : PULMONARY HYPERTENSION</li> <li>- AOP Orphan Pharmaceuticals : PULMONARY HYPERTENSION</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul>
Galie Nazzareno	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Pfizer : Pulmonary Hypertension</li> <li>- Actelion : Pulmonary Hypertension</li> <li>- Ferrer International : Pulmonary Hypertension</li> </ul> Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gin-Sing Wendy	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> <li>- Acceleron : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- membership of the PHA-UK</li> </ul>
Granton John	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Janssen Pharmaceuticals : Pulmonary HYPertension</li> <li>- Bayer Healthcare : Pulmonary Hypertension / chronic thromboembolic pulmonary hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Granton John	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- Member, Canadian Thoracic Society Executive - past president.</li> </ul>
Gruenig Ekkehard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : research grants and speaker honoraria / consultancy fees outside the submitted work</li> <li>- Actelion : research grants and speaker honoraria / consultancy fees outside the submitted work</li> </ul>
Gumbiene Lina	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Janssen : clinical study investigator</li> <li>- Johnson &amp; Johnson : speaker fee</li> <li>- Medis Pharma : speaker fee</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : ESC virtual congress participation fee</li> </ul>
Hassoun Paul M	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : I serve on a Scientific Advisory Board</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Hayrapetyan Hamlet	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial Hypertension, Coronary Heart Diseases</li> <li>- Egis Pharma : Arterial Hypertension, Dyslipidemia</li> <li>- Novartis : Heart Failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Tricida Inc. : Chronic Kidney Disease</li> </ul>
Hellemons Merel Elise	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : COVID-19</li> </ul>
Hirsch Rafael	<p><b>2021</b></p> <p>Nothing to be declared</p>
Hizoh Istvan	<p><b>2021</b></p> <p>Nothing to be declared</p>
Ibrahimi Pranvera	<p><b>2021</b></p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : heart failure</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Jansa Pavel	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension</li> <li>- Bayer Healthcare : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary hypertension</li> </ul>
Kiwan Ghassan S	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : NOAC DOAC</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NOAC DVT</li> </ul>
Kjellstrom Barbro	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : PAH and CTEPH, registry studies</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Chair of the Swedish PAH regsitry SPAHR Supporting member in the patient/next of kin organisation PAH Sverige</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Klok Erik	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Leo Pharma : Anticoagulation</li> <li>- Boston Scientific : Pulmonary embolism</li> <li>- Actelion : Pulmonary hypertension</li> <li>- Bayer AG : Pulmonary hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Pulmonary hypertension</li> <li>- Actelion : Pulmonary hypertension</li> <li>- Bayer Netherlands : Venous thromboembolism/anticoagulation</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- My research is supported by the Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association and The Dutch Heart Foundation</li> </ul>
Konradi Aleksandra	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertsnion</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul>
Kotecha Dipak	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> <li>- MyoKardia : Trial Advisory Board</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> <li>- Protherics Medicines Development : Systematic review</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself            - Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</p>
Krim Messaad	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself            - Novartis : Heart Failure            - El Kendi : Prasugrel Expertise</p>
Kurzyrna Marcin	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself            - Pfizer : pulmonary embolism            - Janssen-Cilag : pulmonary hypertension            - AOP Orphan Pharmaceuticals : pulmonary hypertension            - Merck Sharp &amp; Dohme : pulmonary hypertension, pulmonary embolism            - Bayer AG : pulmonary hypertension, pulmonary embolism</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself            - Merck Sharp &amp; Dohme : pulmonary hypertension</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kurzyna Marcin	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension</li> </ul>
Lang Irene Marthe	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Neutrolis : Cardiovascular Biology</li> <li>- Actelion : Pulmonary Hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- MSD : Pulmonary Hypertension</li> </ul>
Lankeit Mareike	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Product: Rivaroxaban; Therapeutic Area: Venous Thromboembolism</li> </ul>
Lazareva Irina	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lazaro Salvador Maria	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart Failure</li> <li>- Bayer : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Janssen-Cilag : PULMONARY HYPERTENSION</li> <li>- MSD : PULMONARY HYPERTENSION</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Heart failure</li> </ul>
Lewis Basil S	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Idorsia : Antithrombotics</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Linhart Ales	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Avrobio : Faby disease</li> <li>- Novartis : Heart failure</li> </ul>
Lip Gregory Yh	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi-Sankyo : Anticoagulation</li> <li>- Boehringer Ingelheim : Anticoagulation; Registries; Steering Committees</li> <li>- Pfizer : Anticoagulation; Registries</li> <li>- BMS : Antithrombotic therapy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : AF registries [unrestricted educational grant]</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Shares in private limited company (a legal separate entity in UK), but no salary/dividends/income/personal remuneration received.</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lochen Maja-Lisa	<p><b>2021</b></p> <p>Nothing to be declared</p>
Maher Vincent	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Servier for lecturing</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Research project</li> </ul>
Manginas Athanassios	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Bayer : PAH</li> <li>- Actelion : PAH</li> <li>- Merck Sharp &amp; Dohme : PAH</li> </ul>
Mathioudakis Alexander G	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : COPD Exacerbations</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mathioudakis Alexander G	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - OTHER - Healthy Networks. A start-up company developing an electronic stethoscope paired with lung sound analysis software.</li> </ul>
Mellemkjaer Soren	<p><b>2021</b></p> <p>Nothing to be declared</p>
Meneveau Nicolas	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotic treatments</li> <li>- Boehringer-Ingelheim : Antithrombotic treatments</li> <li>- Bayer Healthcare : Antithrombotic treatments</li> <li>- Bristol Myers Squibb : Antithrombotic treatments</li> <li>- Abbott : OCT (endovascular imaging)</li> <li>- Terumo Inc : OFDI (endovascular imaging)</li> <li>- Edwards Lifesciences : TAVI</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Interventional Cardiology</li> <li>- Boston Scientific : PCI</li> <li>- Biotronik : PCI, CTO</li> </ul>
Micallef Josef	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Michaloliakos Ioannis	<p><b>2021</b></p> <p style="text-align: center;">Nothing to be declared</p>
Mindham Richard	<p><b>2021</b></p> <p>Financial Declaration</p> <p style="padding-left: 40px;">Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <p style="padding-left: 80px;">- Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p style="padding-left: 40px;">Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <p style="padding-left: 80px;">- I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Moledina Shahin	<p><b>2021</b></p> <p>Financial Declaration</p> <p style="padding-left: 40px;">Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <p style="padding-left: 80px;">- Janssen-Cilag : Consultancy pulmonary hypertension trial design/ conduct</p> <p style="padding-left: 80px;">- Altavant sciences : Pulmonary hypertension pharmaceuticals</p> <p>Other Positions of Influence</p> <p style="padding-left: 40px;">Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <p style="padding-left: 80px;">- Medical doctor employed by hospital</p> <p style="padding-left: 40px;">Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <p style="padding-left: 80px;">- Member of pulmonary vascular research institute (PVRI.org)</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mostafa Ahmed Hassan Abdo	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : PAH</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Janssen-Cilag : PAH</p>
Mukarov Murat	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Sanofy : speaker fees</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Bayer : travel expenses</p>
Musayev Ogtay	<p><b>2021</b></p> <p>Nothing to be declared</p>
Mutlu Bulent	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Johnson &amp; Johnson : Investigator - Amgen : Investigator - United Therapeutics : Investigator - Servier : Speaker - Johnson &amp; Johnson : Speaker</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mutlu Bulent	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Johnson &amp; Johnson : ESC Congress</p>
Naeije Robert	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - United Therapeutics : Advisory board - Lung Rx : Advisory board - AOP Orphan Pharmaceuticals : Advisory board, speaker fees - Actelion : IDMC - Johnson &amp; Johnson : IDMC</p>
Nielsen Jens Cosedis	<p><b>2021</b></p> <p>Nothing to be declared</p>
Olschewski Horst	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : Asthma - Novartis : Asthma - Menarini : COPD - Chiesi Pharma : COPD - Boehringer-Ingelheim : COPD, Heart Failure - Pfizer : PAH - Janssen : PAH - Merck Sharp &amp; Dohme : PAH, CTEPH</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Olschewski Horst	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Bayer AG : PH</li> <li>- GlaxoSmithKline : PH, Asthma, COPD</li> <li>- Actelion : PH, CTEPH</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Janssen : PH</li> <li>- Algorithm Sciences : PH</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Board Member of Rene Baumgart Stiftung</li> </ul>
OUARDA TORGEMAN Fatma	<p><b>2021</b></p> <p>Nothing to be declared</p>
Pentikainen Markku Oskari	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Janssen-Cilag : Pulmonary hypertension, Heart failure</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - OTHER - Orion &amp; Oriola (Finland)</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself  - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself  - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Placido Rui	<p><b>2021</b></p> <p>Nothing to be declared</p>
Poglajen Gregor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - Astra Zeneca : Heart failure  - Bayer : Heart failure  - Novartis : Heart failure  - Boehringer Ingelheim : Heart failure</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Post Marco	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : speaker fees</li> <li>- MSD : speaker fees</li> </ul>
Prescott Eva	<p><b>2021</b></p> <p>Nothing to be declared</p>
Rakisheva Amina	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul>
Reis Abilio	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag: Speaker and Advisory board fees : Pulmonary Hypertension</li> </ul>
Ristic Arsen	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Novartis : Heart failure</li> <li>- Berlin Chemie AG : Heart failure</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Ristic Arsen	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Actavis : Heart failure</li> <li>- Astra Zeneca : Heart Failure (Forxiga)</li> <li>- Boehringer-Ingelheim : Heart Failure (Jardiance)</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Sandoz : Pulmonary hypertension</li> <li>- Hemofarm Stada : Pulmonary hypertension</li> <li>- Pfizer : Pulmonary hypertension, TTR Amyloidosis</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- CSL Behring : Cardiovascular risk - Secondary prevention</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Pfizer : Pulmonary hypertension</li> <li>- United Therapeutics : Pulmonary hypertension</li> <li>- GossamerBio : Pulmonary hypertension</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Obesity</li> <li>- Pfizer : Pulmonary hypertension</li> <li>- Arena/United Therapeutics : Pulmonary Hypertension</li> </ul>
Roche Nicolas	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : COPD</li> <li>- Pfizer : COPD</li> </ul>



## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Roche Nicolas	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Astra Zeneca : COPD/Asthma</li> <li>- Novartis : COPD/Asthma</li> <li>- Sanofi Aventis : COPD/Asthma</li> <li>- GlaxoSmithKline : COPD/Asthma</li> <li>- Chiesi Pharma : COPD/Asthma</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer Ingelheim : COPD</li> <li>- GSK : COPD</li> </ul>
Rodrigues Rita	<p><b>2021</b></p> <p style="text-align: center;">Nothing to be declared</p>
Rudzitis Ainars	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : AH, dyslipidemia</li> <li>- Bayer AG : Oral anticoagulation</li> <li>- Boehringer-Ingelheim : SGLT2i</li> </ul>
Schmitt-Opitz Isabelle	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Advisory Board</li> <li>- MSD : Advisory Board</li> <li>- Astra Zeneca : Speakers Bureau</li> <li>- Roche Pharma : Speakers Bureau</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Schmitt-Opitz Isabelle	<p><b>2021</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Institutional Grant</li> <li>- Roche Pharma : Institutional Grant</li> </ul>
Schwerzmann Markus	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> <li>- Orpha Suisse : Pulmonary Hypertension</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Orpha Suisse : Pulmonary hypertension</li> </ul>
Selton-Suty Christine	<p><b>2021</b></p> <p>Nothing to be declared</p>
Simkova Iveta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension</li> </ul>
Sirenko Yuriy	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Pulmonary Hypertension</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Soderberg Stefan	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipids</li> <li>- Actelion : Pulmonary arterial hypertension</li> </ul>
Sokolovic Sekib	<p><b>2021</b></p> <p>Nothing to be declared</p>
Sooronbaev Talant	<p><b>2021</b></p> <p>Nothing to be declared</p>
Souza Rogerio	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Pulmonary Hypertension</li> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Accelleron : Pulmonary Hypertension</li> </ul>
Srbinovska-Kostovska Elizabeta	<p><b>2021</b></p> <p>Nothing to be declared</p>
Swift Andrew James	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : CT analysis</li> <li>- Janssen-Cilag : Pulmonary hypertension imaging consultancy</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Swift Andrew James	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Janssen-Cilag : Congress attendance</p> <p>Research funding (personal) from healthcare industry.For yourself - GlaxoSmithKline : COVID research</p>
Touyz Rhian	<p><b>2021</b></p> <p>Nothing to be declared</p>
Tsverava Mikheil	<p><b>2021</b></p> <p>Nothing to be declared</p>
Ulrich Silvia	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : Pulmonary Hypertension - Merck Sharp &amp; Dohme : Pulmonary Hypertension</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Janssen-Cilag : Exercise and altitude exposure in patients with pulmonary Hypertension</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of the PH-patient association in Switzerland</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Vasiltseva Oksana	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulant therapy</li> <li>- Pfizer : anticoagulant therapy</li> <li>- Astra Zeneca : antiplatelet therapy</li> <li>- Johnson &amp; Johnson   Janssen : pulmonary hypertension</li> <li>- Bayer : pulmonary hypertension, anticoagulant therapy</li> </ul>
Vataman Eleonora	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Egis Pharma : consultancy</li> <li>- Berlin Chemie AG : speaker fee</li> </ul>
Velchev Vasil	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Pfizer : Eliquis</li> <li>- Boston Scientific : renal denervation</li> <li>- Bayer : xarelto</li> </ul>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Wilkins Martin	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Actelion : Biomarker discovery</li> <li>- GSK : Data safety monitoring</li> <li>- morphogenIX : Drug target advice</li> <li>- Novartis : Protocol development</li> <li>- Acceleron : Study adjudication committee</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of Pulmonary Vascular Research Institute, a charitable body.</li> </ul>
Wort John	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary Hypertension</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : Pulmonary Hypertension</li> <li>- Acceleron : Pulmonary Hypertension</li> </ul>
Zavatta Marco	<p><b>2021</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Aboyans Victor	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Bristol Myers Squibb : Antithrombotic therapies</li> <li>- Astrazeneca : Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Peripheral Artery Disease</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Astrazeneca : Diabetes</li> <li>- Boehringer Ingelheim : Diabetes</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of the French Society of Cardiology</li> </ul>
Antoniou Sotiris	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees for education - AF</li> <li>- Bayer AG : speaker fees for education - AF</li> <li>- Daiichi Sankyo : speaker fees for education -AF</li> <li>- Astra Zeneca : speaker fees for education - CVD</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Joint working initiative on improving CV care</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : speaker fees for education - AF - Bayer AG : speaker fees for education - AF - Daiichi Sankyo : speaker fees for education -AF - Astra Zeneca : speaker fees for education - CVD - Boehringer-Ingelheim : speaker fees for education - CVD</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p>
Arbelo Elena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Atrial fibrillation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Arbelo Elena	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial fibrillation</li> </ul>
Asteggiano Riccardo	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> <li>- Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Council of Cardio-Oncology ESC : cardio-oncology</li> </ul>
Baigent Colin	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Cardiovascular and renal disease</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Renal disease</li> </ul>
Baumbach Andreas	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Pharmacology</li> <li>- CERC : Research Organisation: Events Committees</li> <li>- Abbot Vascular : Stents</li> <li>- Microport : Stents</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Baumbach Andreas	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Sinomed : Stents</li> <li>- Venus Medtech : Valves, CEP</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet</li> <li>- Faraday : Infarct size reduction</li> <li>- Microport : Stents</li> <li>- Sinomed : Stents</li> <li>- Medtronic : Valves</li> <li>- Pi-Cardia : Valves</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Abbot Vascular : OCT</li> </ul>
Borger Michael A	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Borger Michael A	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Medtronic : heart valve therapy</li> </ul>
Celutkiene Jelena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Amgen : heart failure</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : heart failure</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation, amyloidosis</li> <li>- Astra Zeneca : coronary heart disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Orion : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure</li> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- GE Healthcare : Cardiovascular ultrasound</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Amicus Therapeutics : Fabry disease</li> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> <li>- Krka Pharma : Heart failure</li> <li>- Llvanova : Heart failure</li> <li>- Novartis : Heart failure, hyperlipidaemia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Collet Jean-Philippe	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Astra Zeneca : Post-PCI antiplatelet treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p><b>2020</b> - Bristol Myers Squibb : Post-TAVR antithrombotic treatment</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : post PCI antithrombotic therapy</li> <li>- Pfizer : POST PCI ANTITHROMBOTIC THERAPY</li> <li>- Terumo Inc : POST PCI ANTITHROMBOTIC THERAPY</li> <li>- Bristol Myers Squibb : Post-TAVI antithrombotic treatments</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : post tavi antithrombotic therapy</li> <li>- Bristol Myers Squibb : post-tavi antithrombotic therapy</li> </ul>
Falk Volkmar	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> <li>- Boston Scientific : Study</li> <li>- Biotronik : Study</li> <li>- Liva Nova : Study</li> </ul>
Fauchier Laurent	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- XO : Healthcare</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Healthcare</li> <li>- Bayer : Healthcare</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- Novo-Nordisk : Healthcare</li> <li>- Zoll Medical : Healthcare</li> <li>- XO : Healthcare</li> </ul>
Gale Christopher Peter	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acs hf</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : af</li> <li>- Abbott : diabetes</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : ACS</li> <li>- Chiesi Pharma : ACS</li> <li>- Astra Zeneca : ACS Hf</li> <li>- Boehringer-Ingelheim : AF</li> <li>- Daiichi Sankyo : AF</li> <li>- Menarini : CAD</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Bayer : CVD</li> <li>- Zydus : CVD</li> <li>- Oxford University Press : EHJQCCO</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : AF</li> <li>- Abbott : Diabetes</li> <li>- European Society of Cardiology : EuroHeart</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <ul style="list-style-type: none"> <li>- Wondrmedical</li> </ul>
Halvorsen Sigrun	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Sanofi Aventis : Lipidlowering</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart failure</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation -speaker fee</li> <li>- Bristol Myers Squibb : Anticoagulation- speaker fee</li> <li>- Novartis : heart failure - speaker fee</li> </ul>
Iung Bernard	<p><b>2020</b></p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p><b>2020</b></p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : heart failure</li> </ul>
Konradi Aleksandra	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<b>2020</b> - Servier : hypertsniion
	<b>2021</b> Financial Declaration - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension - Servier : hypertsniion
Koskinas Konstantinos	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Cardiology - Daiichi Sankyo : Cardiology  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Cardiology
	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Cardiology - Daiichi Sankyo : Cardiology  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Cardiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> <li>- MyoKardia : Trial Advisory Board</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> <li>- Protherics Medicines Development : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>
Landmesser Ulf	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory Board fee</li> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Bayer AG : Research Grant</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> <li>- Sanofi Aventis : Speaker fee</li> <li>- Bayer AG : Speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Amgen : Research grant</li> <li>- Bayer AG : Research Grant</li> </ul>
Lewis Basil S	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Vifor International : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Idorsia : Antithrombotics</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
Linhart Ales	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Linhart Ales	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Avrobio : Faby disease</li> <li>- Novartis : Heart failure</li> </ul>
Lochen Maja-Lisa	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Mindham Richard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Imperial College, London : 3 honoraria totalling GB£500/€550, passed in full to UK charity, CardiomyopathyUK. There will be no more honoraria.</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- I support actively the British charity CardiomyopathyUK and make a monthly payment to support their activites. I also passed the three honoraria in 2A to CardiomyopathyUK, in full.</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Re item 7A: I have shares which are held inside and outside of a pension. I am unaware of what the shares are as they are all managed by a portfolio manager. Consequently I do not know whether I hold any shares in healthcare or healthcare-related companies, or in media or education companies.</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself            - Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself            - I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Nielsen Jens Cosedis	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself            - Member of Danish Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself            - I received institutional research grants from the Novo Nordisk Foundation</p> <hr/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Petersen Steffen Erhard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself            - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself            - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself            - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself            - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself            - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself            - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Prescott Eva	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rakisheva Amina	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul>
Sitges Marta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Rovi : Heart Failure</li> <li>- Amgen : Hypercholesterolemia</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>
Touyz Rhian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Consultancy-expert opinion</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - Independent Research Methodologist

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

<b>Expert</b>	<b>Type of Relationship with Industry</b>
Morgan Rebecca	<b>2021</b> Nothing to be declared
Sivakumaran Kapeena	<b>2021</b> Nothing to be declared